Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 392.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,552 shares of the biopharmaceutical company’s stock after buying an additional 128,776 shares during the period. SG Americas Securities LLC owned approximately 0.13% of Catalyst Pharmaceuticals worth $4,000,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of CPRX. Smartleaf Asset Management LLC boosted its holdings in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the period. Clearstead Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the period. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,564 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth $39,000. Finally, Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at $40,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CPRX shares. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Finally, Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Down 0.1%

NASDAQ:CPRX opened at $31.46 on Tuesday. The company has a market cap of $3.85 billion, a PE ratio of 18.08, a P/E/G ratio of 0.96 and a beta of 0.74. The business’s 50 day moving average is $30.49 and its two-hundred day moving average is $26.29. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).